Biocryst Pharmaceuticals (BCRX) Share-based Compensation (2010 - 2026)

Biocryst Pharmaceuticals has reported Share-based Compensation for 17 years, with the latest figure at $16.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 25.0% year-over-year to $16.0 million; the trailing twelve-month figure through Mar 2026 stood at $79.7 million (up 9.02% YoY), and the FY2025 full-year result was $85.1 million, up 30.04% from the prior year.
• Share-based Compensation for Q1 2026 stood at $16.0 million, down from $23.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $23.8 million in Q4 2025, with the low at $9.6 million in Q1 2022.
• Historically, Share-based Compensation has averaged $15.7 million across 5 years, with a median of $15.3 million in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 79.79% — and 2026, when it decreased 25.0%.
• Biocryst Pharmaceuticals' Share-based Compensation stood at $15.3 million in 2022, then increased by 7.89% to $16.5 million in 2023, then advanced by 29.42% to $21.3 million in 2024, then grew by 11.5% to $23.8 million in 2025, then slumped by 32.64% to $16.0 million in 2026.
• The last three Share-based Compensation figures came in at $16.0 million (Q1 2026), $23.8 million (Q4 2025), and $18.6 million (Q3 2025), per Business Quant data.